Other covariates adjusted for in multivariate analyses included baseline demographics, cumulative follow-up time, CD4+ T cell count categorized as < or ≥200 cells/mm3, and HIV-1 RNA level categorized as ≤ or >5 log10 (100,000) copies/mL.
Multivariate analyses from baseline data used the Cox proportional hazards model.
Not knowing GHb test results was the only outcome difference that was statistically significant both in the univariate and in the multivariate analyses at baseline.
Although controlled in the multivariate analyses, the baseline and endline study groups differed in several ways, which could have influenced our results.
On multivariate analyses, lower baseline disability scores, family engagement with the programme, medication adherence and being a member of a self-help group were independent determinants of good outcomes.
In multivariate analyses relating baseline measures while adjusting for follow-up potential confounders (age, sex, height, heart rate, PWD use), lower E/I ratio, lower HDL cholesterol, and a history of smoking were associated with greater follow-up AIx and Ln AP) (Table 3).
Multivariate analyses including baseline factors that were associated with SVR revealed that the reductions of HCV RNA level at both 4 and 12 weeks after starting therapy were independent factors associated with SVR, and the reduction at 4 weeks had a second strongest impact for SVR, following genetic polymorphisms of rs8099917 near IL28B gene.
In multivariate linear regression analyses, baseline pain severity was independently associated with greater levels of depression, but not with smoking status.
Multivariate analyses adjusted for baseline and treatment factors.
Pooled univariate and multivariate analyses (N=1684) identified baseline factors associated with an increased benefit of belimumab versus placebo.
